Madrigal Pharmaceuticals on Thursday reported highly anticipated results for its Phase 2 non-alcoholic steatohepatitis (NASH) drug MGL-3196, unveiling positive data after 36 weeks. The study …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
